In specific subsets of AM, other monoclonal antibodies have been used, often alongside corticosteroids or as a second-line therapy after corticosteroid failure.81 Alemtuzumab, which targets CD52 on B and T cells and is indicated for multiple sclerosis, has shown potential efficacy in ICI-related AM.82 Muronomab has successfully been used in ICI-related myocarditis and in GCM.83 It targets CD3, a glycoprotein found on T cells, and is already approved in organ transplant recipients. The gene discussed is CD52; the disease is acute myeloblastic leukemia with maturation.